Discussant - Phase Ia/Ib dose-esc study of the anti-TIGIT  tiragolumab as a single agent and in combination with atezo - Michele Teng #AACR20 $RHHBY $MRK $RCUS $MREO $SGEN 5/x

same Q for DNAM-1/CD226 =&gt; add. indpdt biomarkers to be added?
Treg depletion? https://t.co/g9k2nt4Wxb